Gelrin Technology and Status
Gelrin is a patented hydrogel platform developed at the Technion – Israel Institute of Technology, using crosslinked polymer chains and denatured protein for erosion and resorption.

Regentis Biomaterials makes GelrinC, a cell-free off-the-shelf hydrogel implant that surgeons cure into the knee to treat articular cartilage injuries.
regentis.co.ilCrawled Nov 17, 2026
Gelrin is a patented hydrogel platform developed at the Technion – Israel Institute of Technology, using crosslinked polymer chains and denatured protein for erosion and resorption.
Gelrin is an off-the-shelf, acellular hydrogel platform designed for cartilage repair, preventing cellular migration and aiding hyaline-like cartilage regeneration.
A Pilot/Phase II study of 56 patients treated with GelrinC showed superior improvements in KOOS scores and pain subscale over four years in Northern Europe and Israel.
GelrinC is an acellular, biodegradable implant combining polyethylene glycol di-acrylate (PEG-DA) and denatured fibrinogen, crosslinked with UVA light to form a hydrogel matrix.
GelrinC is implanted in a single step after microfracture treatment, requiring about 10 minutes to apply the liquid hydrogel to fill cartilage defects.
Knee cartilage injuries, caused by acute or repetitive trauma, often fail to heal naturally and may lead to joint degeneration or osteoarthritis without treatment.
The company holds a patent portfolio of 34 issued patents, including 11 U.S. patents and 26 foreign patents, covering aspects of its product family.
Regentis Biomaterials develops hydrogel-based solutions for repairing damaged tissue, with a focus on orthopedic applications to restore patient health.
The company’s privacy policy outlines its online information practices and user choices to protect privacy on regentis.co.il and related sites.
The company prioritizes accessibility, ensuring its site meets Level AA of the W3C Web Content Accessibility Guidelines (WCAG) 2.0 for users with disabilities.
Regentis secures an exclusive deal with AMI Technologies, Israel’s top orthopedics distributor, to market GelrinC®. The agreement includes minimum purchase commitments and targets revenue contributions starting in 2027. AMI Technologies will handle commercialization in Israel’s orthopedic market.
Regentis secures European regulatory approval for an advanced GelrinC manufacturing process that boosts production yield by 400%, enabling scalable commercial output. The process, validated by a European Notified Body, also reduces manufacturing costs and enhances safety. The approval supports Regentis’ preparations for its upcoming European market launch.
Regentis’ GelrinC regenerates cartilage structures resembling native hyaline cartilage in knee repair patients, as confirmed by MRI results. Two years post-treatment, treated patients exhibit layered cartilage architecture matching the gold standard for joint durability. The findings use a validated, regulator-accepted method for verification.
Regentis Biomaterials secures expanded CE Mark approval in the EU for its **GelrinC** hydrogel-based resorbable treatment, now covering products manufactured with **denatured human fibrinogen**. The approval broadens the product’s use for **focal cartilage defects in the knee**.
Regentis Biomaterials secures $15 million in Series D funding led by Haisco Pharmaceutical Group to advance its U.S. pivotal trial for **GelrinC**, a liquid-based cartilage implant that solidifies into a bioresorbable scaffold. The implant degrades over time, promoting natural cartilage regeneration. The company now proceeds toward clinical validation in the U.S. market.